Diagnosis & Treatment Blogs

Currently, lung cancer screening using low-density computed tomography (LDCT) scans is available as a tool to screen for lung cancer in individuals at high risk of developing the

LUNGevity is excited to announce the launch of the LUNGevity Early Lung Cancer Center (ELCC). The ELCC was created to accelerate the development of early detection and early

While participating in clinical trials can provide substantial benefits to people with lung cancer, the resources required to do so may pose significant hurdles, especially to

A recent court case called Braidwood Management Inc. v. Becerra has received a lot of attention in the public health and cancer patient advocate communities. Current law requires

Our lung tissue is made of different kinds of cells, including neuroendocrine cells. If these cells develop changes in their genome, they can begin to grow out of control and

The point at which lung cancer is diagnosed plays a key role in treatment and survival. The average 5-year survival rate for lung cancer diagnosed while still localized (stage I)

Participating in a clinical trial gives patients the ability to try the newest treatments that otherwise are not available. There are many ongoing clinical trials testing new lung cancer treatments, including targeted therapies, chemotherapy, radiation therapy, and immunotherapy, alone and in combination.

Paul K. Paik, MD, medical oncologist and researcher at Memorial Sloan Kettering Cancer Center and a member of LUNGevity’s Scientific Advisory Board, sat down to talk about what squamous cell lung cancer is and where we stand with treatment options for this disease.

Communication is critical to a positive doctor-patient relationship. Knowing the right questions to ask helps ensure you leave your appointments with the information and answers

For World Cancer Day this year, the Union for International Cancer Control presents the #CloseTheCareGap initiative. February 4, 2023 will be a day focused on promoting equity in

While targeted therapies have emerged in the past decade to improve treatment of non-small cell lung cancer (NSCLC) with some types of driver mutations (such as EGFR and ALK), lung

On June 1st, 2022, LUNGevity Foundation hosted a Facebook Live to discuss our manuscript titled “ The 2021 Global Lung Cancer Therapy Landscape” published in the Journal of